Search the Newsreel

Apogee Therapeutics Inc. $APGE Shares Acquired by Bank of New York Mellon Corp

AbbVie Inc. Q2 2026 Earnings Call Summary

AbbVie Inc. Q2 2026 Earnings Call Summary - Moby Strategic Performance and Market Dynamics Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. …

Vanguard Portfolio Management (APOG) discloses 5.67% beneficial stake in Apogee

Vanguard Portfolio Management LLC, along with its affiliates, has reported a beneficial ownership of 5.67% in Apogee Enterprises Inc, amounting to 1,183,872 shares. This disclosure, filed on an amended Schedule 13G, indicates that Vanguard holds sole voting power over 21,649 shares and sole dispositive …

Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE

Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Apogee Therapeutics, Inc. (NasdaqGM: APGE) to AbbVie (NYSE: ABBV). Shareholders of Apogee are set to receive $135.11 in cash per share. KSF is scrutinizing whether this price and the process leading to …

Apogee Enterprises, Inc. Revenue Breakdown – NASDAQ:APOG

Apogee Enterprises, Inc. (NASDAQ: APOG) generated $1.40 billion USD in revenue last year. Its top-performing segment, Architectural Metals, contributed $503.75 million USD, while the United States was the largest regional contributor at $1.34 billion USD. This data provides a concise overview of the company's …

Apogee Therapeutics, Inc. Revenue Breakdown – BOATS:APGE

This article provides financial information for Apogee Therapeutics, Inc. (APGE). It outlines various financial data including statements, statistics, dividends, earnings, and segments. The content is primarily a data and navigational page from TradingView, focusing on investment tools and market data for APGE.

Is Apogee Therapeutics Inc. (APGE) Stock Outpacing Its Medical Peers This Year?

Apogee Therapeutics Inc. (APGE) is outperforming its Medical sector peers this year with a 77.9% gain, significantly higher than the sector's 0.8% average return. The stock holds a Zacks Rank #2 (Buy), and its full-year earnings consensus estimate has increased, indicating stronger analyst sentiment. …

APOG|Apogee Enterprises Inc|Price:40.940|Chg%:+0.200

TradingKey provides a comprehensive stock analysis of Apogee Enterprises Inc (APOG), noting its relatively stable fundamentals, high growth potential, and "fairly valued" status within the Homebuilding & Construction Supplies industry. The company is highlighted for its high institutional ownership, analyst "Buy" ratings, and strong …

APGE|Apogee Therapeutics Inc|Price:134.310|Chg%:+0.030

This article provides a detailed financial overview of Apogee Therapeutics Inc (APGE), presenting its latest market data, earnings information, and key financial statements. It includes quarterly and annual data for EPS, Net Profit, Balance Sheet particulars like assets and liabilities, and Cash Flow metrics. …

Apogee Enterprises Inc (APOG) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Apogee Enterprises Inc (APOG), detailing its current risk score of 5.86 and ranking within the Homebuilding & Construction Supplies industry. It highlights the company's beta value of 1.16, indicating higher historical volatility compared to the S&P 500. …

Apogee Enterprises Inc (APOG) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Apogee Enterprises Inc (APOG), covering its support and resistance levels, various technical indicators, and moving averages. The stock's current price momentum score is 4.34, and it is trading between a resistance level of $46.98 and a support …

Apogee Therapeutics Inc (APGE) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Apogee Therapeutics Inc (APGE), detailing its support, resistance, indicators, and moving averages. According to TradingKey, the overall technical signal for APGE is Neutral, with specific indicators showing mixed signals (e.g., RSI and Williams %R are Overbought, while …

Liquidity Mapping Around (APOG) Price Events

Quantitative Research Desk has published an analysis on Apogee Enterprises Inc. (APOG), indicating a neutral sentiment across all time horizons. The report highlights a mid-channel oscillation pattern and presents three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles. Key findings …

Apogee Therapeutics Inc (APGE) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis for Apogee Therapeutics Inc (APGE), focusing on its PE, PB, and fair value. It displays current market data including the stock price, daily change, market capitalization, and a placeholder for P/E TTM, suggesting that detailed financial analysis is …

First Light Asset Management LLC Increases Stock Holdings in Apogee Therapeutics Inc. $APGE

Apogee Therapeutics Inc (APGE) Institutional Confidence

This article from TradingKey provides an overview of Apogee Therapeutics Inc.'s (APGE) institutional confidence, detailing major institutional shareholders and their recent activity. Key investors like T. Rowe Price Investment Management, Inc., VR Adviser, LLC, and Fidelity Management & Research Company LLC are listed along …

Apogee Enterprises Inc (APOG) Income Statement

This article provides the quarterly and annual income statements for Apogee Enterprises Inc (APOG), offering detailed financial data such as total revenue, operating expenses, net income, and earnings per share. It allows investors to analyze the company's financial performance and operational efficiency over various …

Apogee Therapeutics Inc (APGE) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Apogee Therapeutics Inc (APGE), detailing its volatility, financial risk, and investment risk metrics. It includes data on beta, Value at Risk (VaR), maximum drawdown, volatility, return statistics, Sharpe ratio, and liquidity measures over various timeframes. The information …

Apogee Therapeutics Inc (APGE) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Apogee Therapeutics Inc (APGE), highlighting current analyst ratings, target prices, and historical and projected EPS. Based on 15 analysts, the stock currently holds a "Hold" rating with an expected upside space of -2.75%. The article also includes …

Apogee Enterprises Inc (APOG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Apogee Enterprises Inc (APOG), focusing on its regional contributions. As of April 6, the company's revenue is primarily derived from the United States, which accounts for 92.50% of the total, followed by Canada and Brazil. Data for …

Apogee Therapeutics Inc (APGE) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Apogee Therapeutics Inc (APGE), listing major institutional holders and their respective proportions. It also presents a breakdown of shareholder types and a historical overview of institutional shareholding, including the number of institutions, shares held, and changes over …

Apogee Enterprises Inc (APOG) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Apogee Enterprises Inc (APOG), listing its major individual shareholders and institutional holdings. Key shareholders include BlackRock Institutional Trust Company, N.A., Vanguard Portfolio Management, LLC, and Dimensional Fund Advisors, L.P. The article also provides historical institutional shareholding data …

Apogee Therapeutics Inc (APGE) Financial Health: Profitability & Balance Sheet Analysis

The article provides a financial analysis of Apogee Therapeutics Inc (APGE), focusing on its profitability and balance sheet. It presents key financial data such as its market capitalization and current stock price. The content is primarily a placeholder for a detailed financial report that …

Granahan Investment Management LLC Has $6.32 Million Stock Position in Apogee Therapeutics Inc. $APGE

Apogee Enterprises (NASDAQ:APOG) Raised to Buy at Wall Street Zen

Wall Street Zen upgraded Apogee Enterprises (NASDAQ:APOG) from "hold" to "buy" after the company reported better-than-expected quarterly results, with EPS of $0.57 against estimates of $0.43 and revenue of $342.68 million. Despite a 1.1% year-over-year revenue decline, the positive earnings and guidance, along with …

Form 4 Apogee Therapeutics Inc For: 24 July By Investing.com

This article from Investing.com reports on a Form 4 filing for Apogee Therapeutics Inc (APGE) for transactions that occurred on July 24. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a …

Apogee Therapeutics (APGE) CFO makes bona fide gift of 15,000 shares

Apogee Therapeutics' Chief Financial Officer, Jane Henderson, reported a bona fide gift of 15,000 shares of common stock to a donor-advised fund. This transaction was not executed under a Rule 10b5-1 plan, and following the transfer, Henderson directly holds 158,371 shares of APGE. The …

Bruce & Co. Inc. Takes Position in Apogee Enterprises, Inc. $APOG

Bruce & Co. Inc. recently established a new position in Apogee Enterprises, acquiring 50,000 shares valued at approximately $1.68 million during the first quarter. This investment constitutes 0.5% of Bruce & Co.'s portfolio and 0.24% of Apogee's outstanding shares. The timing follows Apogee's strong …

Understanding Momentum Shifts in (APGE)

This article analyzes Apogee Therapeutics Inc. (NASDAQ: APGE), noting neutral near and mid-term readings but a positive long-term bias. It highlights the absence of resistance levels above the current price, suggesting upside potential. The piece also details AI-generated institutional trading strategies (Position, Momentum Breakout, …

APOG|Apogee Enterprises Inc|Price:40.290|

Apogee Enterprises Inc. (APOG) is currently trading at $40.800 with a market cap of $865.78M. The company's fundamentals are stable with high growth potential and its valuation is considered fairly valued. Analysts have rated it as a "Buy" with a target price of $46.83, …

Major Purchase Alert: Christopher W. Ede Invests $402K In Apogee Enterprises Stock

Christopher W. Ede, President at Apogee Enterprises (NASDAQ: APOG), recently made a significant insider purchase of 10,115 shares totaling $402,475. This transaction occurred on July 21, and is seen as a potential indicator of his confidence in the company's future performance. Despite a recent …

3 Reasons to Buy AbbVie Stock Like There's No Tomorrow

AbbVie (NYSE: ABBV) has performed fairly well this year despite significant volatility. The company's shares are up 10%, slightly above the S&P 500's 8% return. Will the healthcare leader maintain this momentum? Some may worry that AbbVie faces significant near-term risks, given the continued …

Apogee Enterprises President, Architectural Glass Christopher W. Ede files initial beneficial ownership statement

Christopher W. Ede, President of Architectural Glass at Apogee Enterprises, has filed an initial beneficial ownership statement reporting 16,168 shares of common stock. This filing was dated July 6, 2026, and the information was sourced from a document published via EDGAR on July 21, …

Apogee Therapeutics stock hits all-time high at 134.34 USD

Apogee Therapeutics stock reached an all-time high of $134.34 USD, marking a significant milestone with a 243% increase over the past year and a market capitalization of $10.05 billion. The company is set to be acquired by AbbVie for $135.11 per share, following advancements …

Apogee Enterprises (NASDAQ: APOG) grants 10,115-share stock awards to senior executive

Apogee Enterprises (NASDAQ: APOG) has granted 10,115 shares of common stock to its President, Architectural Glass, Ede Christopher Willliam, through two time-vested awards on July 6, 2026. The awards, priced at $39.79 per share, include one for 5,026 shares vesting in 2028 and another …

How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend?

Key Points AbbVie will fund this acquisition with debt, leaving its cash reserves intact. The company should maintain its dividend program as it did after previous massive acquisitions. 10 stocks we like better than AbbVie › On June 22, AbbVie(NYSE: ABBV) announced that it …